within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01C_CardiacStimulantsExclCardiacGlycosides.C01CE02_Milrinone;
model Milrinone 
   extends Pharmacolibrary.Drugs.ATC.C.C01CE02;

  annotation(Documentation(
    info ="<html><body><p>Milrinone is a phosphodiesterase 3 inhibitor used mainly for the short-term treatment of acute decompensated heart failure and for patients with severe heart failure unresponsive to conventional therapy. It produces positive inotropic and vasodilatory effects. Milrinone is approved and utilized in hospital settings, particularly in intensive care.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with congestive heart failure after intravenous administration.</p><h4>References</h4><ol><li><p>Bailey, JM, et al., &amp; Hug, CC (1994). Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery. <i>Anesthesiology</i> 81(3) 616–622. DOI:<a href=&quot;https://doi.org/10.1097/00000542-199409000-00014&quot;>10.1097/00000542-199409000-00014</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8092507/&quot;>https://pubmed.ncbi.nlm.nih.gov/8092507</a></p></li><li><p>Stroshane, RM, et al., &amp; Edelson, J (1984). Oral and intravenous pharmacokinetics of milrinone in human volunteers. <i>Journal of pharmaceutical sciences</i> 73(10) 1438–1441. DOI:<a href=&quot;https://doi.org/10.1002/jps.2600731029&quot;>10.1002/jps.2600731029</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6502494/&quot;>https://pubmed.ncbi.nlm.nih.gov/6502494</a></p></li><li><p>Lehtonen, LA, et al., &amp; Pentikäinen, PJ (2004). Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. <i>Clinical pharmacokinetics</i> 43(3) 187–203. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200443030-00003&quot;>10.2165/00003088-200443030-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/14871156/&quot;>https://pubmed.ncbi.nlm.nih.gov/14871156</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Milrinone;
